Connect with us

Business

Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch

Published

on

Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch


A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.

George Frey | Bloomberg | Getty Images

Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill for obesity.

In a Friday note, TD Cowen analysts called it a “solid start” for the first-ever weight loss pill, but said “one data point does not make a trend.” They cautioned that they need to see more data to fully assess early demand for the Wegovy pill, which officially launched Jan. 5 after winning approval in late December. 

Still, the initial data is a boost to the Danish drugmaker’s hopes of winning back more share from its chief rival, Eli Lilly, this year in the booming obesity and diabetes drug market. Eli Lilly won the majority market share in early 2025 and is trailing closely behind Novo Nordisk in the pill space, as it prepares for the upcoming launch of its own oral drug for obesity.

In a Friday note, Leerink Partners analyst David Risinger said around 3,100 prescriptions for the Wegovy pill were filled in the first week of the launch, citing IQVIA data for the week ending Jan. 9. In the first week of the commercial launch of Eli Lilly’s popular obesity injection, Zepbound, around 1,300 prescriptions were filled, and roughly 8,000 were filled in the second week, he noted. That injection won U.S. approval in late 2023. 

The TD Cowen analysts cited somewhat different data published by Symphony through Bloomberg.

The analysts said around 4,290 prescriptions were filled for Novo Nordisk’s pill during its first full week of launch, with the majority being for the starting dose of the drug. They added that the data from their source or IQVIA likely don’t include prescriptions through Novo Nordisk’s direct-to-consumer pharmacy or its telehealth partners. 

The analysts said that compares with the roughly 1,900 prescriptions filled for Zepbound during its first full week on the market.

Assuming the Symphony data is accurate, the pill “is already outstripping its injectable counterparts at the same stage of their launch,” TD Cowen analyst Michael Nedelcovych wrote in the note. A more direct comparison between the pill and the injections can be made based on available data early next week, though the figures may not prove more useful for another two to three quarters, he added. 

Nedelcovych said he wants to see the full picture on the direct-to-consumer channel, which holds “significant promise” for the pill’s launch. 

Demand could also shift once Eli Lilly’s pill, orforglipron, enters the market in the next few months, he added.

While Novo Nordisk’s drug has a head start, it is a peptide medication with dietary requirements — no food or drink for 30 minutes after taking the pill with water — that may hinder uptake. Eli Lilly’s pill is a small-molecule drug and not a peptide, meaning it does not have those restrictions. 



Source link

Business

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

Published

on

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease


Thomas Fuller | SOPA Images | Lightrocket | Getty Images

UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.

The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.

“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”

The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.

UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.

The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”

UniQure didn’t immediately comment.

The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.



Source link

Continue Reading

Business

US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India

Published

on

US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India


The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.



Source link

Continue Reading

Business

PSX reclaims 160k level with 5,433-point jump | The Express Tribune

Published

on

PSX reclaims 160k level with 5,433-point jump | The Express Tribune


Foreign funds would divert their liquidity into buying Pakistan’s stocks. This would merely increases prices of shares and be profitable for those who already hold stocks. PHOTO: FILE


KARACHI:

The Pakistan Stock Exchange on Thursday staged a powerful rebound, when the benchmark KSE-100 index surged by over 5,400 points, reclaiming the 160,000 level in a decisive rally driven by strong institutional buying and renewed investor confidence.

The session marked a sharp recovery from recent volatility as bulls took control from the opening bell. Index-heavy stocks like Hubco (+7.15%), OGDC (+8.24%) and others led the charge, contributing significantly to the gains, while trading volumes rose to 724 million shares valuing at Rs35 billion. K-Electric dominated the volumes with over 115 million shares traded.

At the close of trading, the KSE-100 index posted a strong gain of 5,433.46 points, or 3.49%, and settled at 161,210.68.

According to Arif Habib Limited (AHL), the stock market staged a strong rebound as the benchmark index pushed higher from its 200-day moving average, gaining 3.49% to reclaim the 160,000 level. Market participation remained broadly positive, with 85 shares advancing while 14 declined among key index movers.

The major contributors included Hubco, which rose 7.15%, OGDC, higher by 8.24%, and Fauji Fertiliser, which despite declining 2.93% remained among the notable stocks influencing index movements. On the downside, Abbott Laboratories fell 3.5%, Highnoon Laboratories declined 2.42% and Fatima Fertiliser slipped 0.82%, emerging as the biggest drags on the index.

Meanwhile, geopolitical and macroeconomic developments also remained in focus. Pakistan’s top military leader stated that the country was willing to halt operations against Afghanistan if the Taliban government stopped supporting terror groups operating from its territory. On the economic front, Saudi authorities assured Pakistan of secure energy supplies through the Port of Yanbu on the Red Sea, helping support the country’s energy requirements, it said.

Additionally, Pakistan was preparing to introduce several measures, including weekly petroleum price revisions, compensation to oil companies for higher insurance costs and import premiums, and fuel conservation initiatives. Finance Minister Muhammad Aurangzeb also assured a parliamentary panel that Pakistan had adequate petroleum reserves, including 28 days of petrol and diesel supply.

Despite the strong rebound during the session, the market remained down about 4% week-on-week while heading into the final trading day and continued to trade within the large gap created by Monday’s sharp decline, AHL said.

“Bulls stormed back with authority in Thursday’s trading session, firmly planting their feet from the outset,” Topline Securities stated in its review. Strong institutional buying turned the tide after the market’s recent overreaction to regional issues, as confidence swiftly replaced caution.

Momentum gathered strength as the session progressed, driving the index to the intra-day high of 5,699 points before closing at 161,211 – up 5,433 points. It was not merely a rebound, but a statement rally marked by decisive accumulation and broad-based strength. Index-heavy constituents including Hubco, OGDC, Fauji Fertiliser, Engro Holdings and Meezan Bank led the charge, collectively contributing 2,197 points to the benchmark’s gain and reinforcing the bullish undertone, Topline said.

During the day, shares of 478 companies were traded. Of these, 350 stocks closed higher, 78 fell and 50 remained unchanged.

K-Electric was the volume leader with trading in 115.6 million shares, gaining Rs0.61 to close at Rs8.05. It was followed by Trust Securities & Brokerage (R) with 50.03 million shares, losing Rs0.04 to close at Rs0.18 and Unity Foods with 48.3 million shares, gaining Rs0.55 to close at Rs10.08. Foreign investors sold shares worth Rs1.4 billion, the National Clearing Company reported.



Source link

Continue Reading

Trending